Since repression of NRF2 begins in early ADPKD, restoring NRF2 activity in the early disease stage offers a promising therapeutic window in reducing cyst formation and improving renal function, without triggering the adverse consequences associated with prolonged NRF2 overactivation. The gene discussed is NFE2L2; the disease is cyst.